TITLE

Weekly Cyclophosphamide and Alternate-Day Prednisone: An Effective, Convenient, and Well-Tolerated Oral Treatment for Relapsed Multiple Myeloma After Autologous Stem Cell Transplantation

AUTHOR(S)
Trieu, Young; Trudel, Suzanne; Pond, Gregory R.; Mikhael, Joseph; Jaksic, Wilfrid; Rhece, Donna E.; Chen, Christine I.; Stewart, A. Keith
PUB. DATE
December 2005
SOURCE
Mayo Clinic Proceedings;Dec2005, Vol. 80 Issue 12, p1578
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: To assess the efficacy and tolerability of weekly oral cyclophosphamide in combination with alternate-day prednisone (CP) as salvage therapy for patients with relapsed multiple myeloma (MM) after autologous stem cell transplantation (ASCT). PATIENTS AND METHODS: We retrospectively reviewed the medical records of all patients identified In our clinical database as having received CP as treatment for relapsed MM after ASCT at Princess Margaret Hospital between July 1998 and May 2004. The CP regimen consisted of oral cyclophosphamide at 500 mg once weekly and oral prednisone at 100 mg on alternate days. RESULTS: A total of 66 patients received the CP regimen, with a median of 2.0 prior therapies (range, 1.0-5.0) from time of diagnosis to initiation of CP. The median time from relapse after ASCT to start of CP therapy was 1.5 months (range, 0.0-23.5 months). Because of nonsecretory disease in 7 patients, only 59 patients were evaluable for response. The median duration of CP treatment was estimated at 5.8 months (95% confidence interval [Cl]. 4.6-7.8 months). With a median follow-up of 15.9 months (range. 1.4-67.2 months). 36 patients (61%) responded to treatment. 24 (41%) of whom had a partial response. The 1-year progression-free survival of all evaluable patients was estimated at 66% (95% Cl. 54%-80%), with a median progression-free survival of 18.6 months (95% Cl, 13.9-29.9 months). The median overall survival from time of initiation of CP was estimated at 28.6 months (95% Cl, 22.1-not available months). CONCLUSION: Our data show that CP is an effective, well-tolerated, and convenient regimen as salvage therapy for MM after ASCT.
ACCESSION #
19168650

 

Related Articles

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics